• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk Factors for Relapse of Human Brucellosis.人类布鲁氏菌病复发的危险因素。
Glob J Health Sci. 2015 Nov 3;8(7):77-82. doi: 10.5539/gjhs.v8n7p77.
2
Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans.庆大霉素联合多西环素与链霉素联合多西环素治疗人类布鲁氏菌病的疗效比较
Clin Infect Dis. 2006 Apr 15;42(8):1075-80. doi: 10.1086/501359. Epub 2006 Mar 13.
3
Clinical profile and management of brucellosis in Tehran - Iran.
Acta Clin Belg. 2009 Jan-Feb;64(1):11-5. doi: 10.1179/acb.2009.004.
4
Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature.1028 例布鲁氏菌病的临床表现和并发症:回顾性评估及文献复习。
Int J Infect Dis. 2010 Jun;14(6):e469-78. doi: 10.1016/j.ijid.2009.06.031. Epub 2009 Nov 11.
5
Epidemiologic, clinical and laboratory findings of patients with brucellosis in Hamadan, west of Iran.伊朗西部哈马丹布鲁氏菌病患者的流行病学、临床和实验室检查结果
J Res Health Sci. 2012 Dec 13;12(2):105-8.
6
Risk factors for human brucellosis in Iran: a case-control study.伊朗人间布鲁氏菌病的危险因素:一项病例对照研究。
Int J Infect Dis. 2008 Mar;12(2):157-61. doi: 10.1016/j.ijid.2007.04.019. Epub 2007 Aug 14.
7
Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis.多西环素-利福平-阿米卡星与多西环素-利福平方案治疗布鲁氏菌病的比较。
Int J Infect Dis. 2007 Mar;11(2):152-6. doi: 10.1016/j.ijid.2005.11.007. Epub 2006 Jun 22.
8
Comparison of two durations of triple-drug therapy in patients with uncomplicated brucellosis: A randomized controlled trial.单纯性布鲁氏菌病患者三联药物治疗两种疗程的比较:一项随机对照试验。
Scand J Infect Dis. 2014 Aug;46(8):573-7. doi: 10.3109/00365548.2014.918275. Epub 2014 Jun 16.
9
Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial.比较 5 天庆大霉素加 8 周多西环素与 2 周链霉素加 45 天多西环素治疗人类布鲁氏菌病的疗效:一项随机临床试验。
J Antimicrob Chemother. 2010 May;65(5):1028-35. doi: 10.1093/jac/dkq064. Epub 2010 Mar 9.
10
Epidemiological features of brucellosis and factors affecting its treatment failure and relapse in Qom Province, Iran.伊朗库姆省布鲁氏菌病的流行病学特征及其治疗失败和复发的影响因素。
Ghana Med J. 2021 Sep;55(3):206-212. doi: 10.4314/gmj.v55i3.5.

引用本文的文献

1
Epidemiological analysis of human brucellosis in North Khorasan province, Iran (2018-2023): a six-year multicenter retrospective study.伊朗呼罗珊省北部人类布鲁氏菌病的流行病学分析(2018 - 2023年):一项为期六年的多中心回顾性研究
BMC Infect Dis. 2025 Sep 1;25(1):1083. doi: 10.1186/s12879-025-11516-y.
2
Proteomics Exploration of to Design an Innovative Multi-Epitope mRNA Vaccine.用于设计创新型多表位mRNA疫苗的蛋白质组学探索。
Bioinform Biol Insights. 2024 Aug 30;18:11779322241272404. doi: 10.1177/11779322241272404. eCollection 2024.
3
Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice.安全的亚单位绿色疫苗可在小鼠中产生强大的免疫力并预防黏膜布鲁氏菌感染。
Vaccines (Basel). 2023 Feb 25;11(3):546. doi: 10.3390/vaccines11030546.
4
Infectious Aneurysm: A Retrospective Study of 14 Cases and Review of the Literature - Case Report and Literature Review.感染性动脉瘤:14例回顾性研究及文献复习——病例报告与文献综述
Infect Drug Resist. 2023 Jan 5;16:87-104. doi: 10.2147/IDR.S393060. eCollection 2023.
5
Femoral Head Necrosis Due to Infection in China: Case Series and Literature Review.中国感染性股骨头坏死:病例系列报道与文献综述
Infect Drug Resist. 2022 Oct 10;15:5857-5865. doi: 10.2147/IDR.S383584. eCollection 2022.
6
Epidemiological features of brucellosis and factors affecting its treatment failure and relapse in Qom Province, Iran.伊朗库姆省布鲁氏菌病的流行病学特征及其治疗失败和复发的影响因素。
Ghana Med J. 2021 Sep;55(3):206-212. doi: 10.4314/gmj.v55i3.5.
7
Short- and long-term follow-up outcomes of patients with Brucella endocarditis: a systematic review of 207 Brucella endocarditis Cases.布鲁氏菌性心内膜炎患者的短期和长期随访结局:207 例布鲁氏菌性心内膜炎病例的系统评价。
Bioengineered. 2021 Dec;12(1):5162-5172. doi: 10.1080/21655979.2021.1962683.
8
Molecular characterization and antimicrobial susceptibility testing of clinical and non-clinical and isolates from Egypt.埃及临床和非临床分离株的分子特征及抗菌药敏试验
One Health. 2021 Apr 27;13:100255. doi: 10.1016/j.onehlt.2021.100255. eCollection 2021 Dec.
9
Brucellosis in Saudi Children: Presentation, Complications, and Treatment Outcome.沙特儿童布鲁氏菌病:临床表现、并发症及治疗结果
Cureus. 2020 Nov 1;12(11):e11289. doi: 10.7759/cureus.11289.
10
Doxycycline-encapsulated solid lipid nanoparticles for the enhanced antibacterial potential to treat the chronic brucellosis and preventing its relapse: in vivo study.载多西环素固体脂质纳米粒增强抗菌作用治疗慢性布鲁氏菌病及其复发的体内研究。
Ann Clin Microbiol Antimicrob. 2019 Nov 9;18(1):33. doi: 10.1186/s12941-019-0333-x.

本文引用的文献

1
A study of knowledge, attitudes and practices relating to brucellosis among small-scale dairy farmers in an urban and peri-urban area of Tajikistan.塔吉克斯坦城市及城郊地区小规模奶农布鲁氏菌病相关知识、态度及行为的研究
PLoS One. 2015 Feb 10;10(2):e0117318. doi: 10.1371/journal.pone.0117318. eCollection 2015.
2
Human brucellosis occurrences in inner mongolia, China: a spatio-temporal distribution and ecological niche modeling approach.中国内蒙古地区人间布鲁氏菌病的发生情况:一种时空分布及生态位建模方法
BMC Infect Dis. 2015 Feb 3;15:36. doi: 10.1186/s12879-015-0763-9.
3
Pathogenesis and pathobiology of brucellosis in livestock.家畜布鲁氏菌病的发病机制与病理生物学
Rev Sci Tech. 2013 Apr;32(1):105-15. doi: 10.20506/rst.32.1.2193.
4
Global burden of human brucellosis: a systematic review of disease frequency.全球人类布鲁氏菌病负担:疾病频率的系统评价。
PLoS Negl Trop Dis. 2012;6(10):e1865. doi: 10.1371/journal.pntd.0001865. Epub 2012 Oct 25.
5
Outcomes of treatment in 50 cases with spinal brucellosis in Babol, Northern Iran.伊朗北部巴博勒50例脊柱布鲁氏菌病患者的治疗结果
J Infect Dev Ctries. 2012 Sep 17;6(9):654-9. doi: 10.3855/jidc.2175.
6
Epidemiological features of human brucellosis in central Iran, 2006-2011.伊朗中部地区 2006-2011 年人间布鲁氏菌病的流行病学特征。
Public Health. 2012 Dec;126(12):1058-62. doi: 10.1016/j.puhe.2012.07.001. Epub 2012 Aug 11.
7
Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis.系统评价和随机临床试验荟萃分析治疗人类布鲁氏菌病。
PLoS One. 2012;7(2):e32090. doi: 10.1371/journal.pone.0032090. Epub 2012 Feb 29.
8
Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial.多西环素-链霉素、多西环素-利福平与氧氟沙星-利福平治疗布鲁氏菌病的比较:一项随机临床试验。
Int J Infect Dis. 2012 Apr;16(4):e247-51. doi: 10.1016/j.ijid.2011.12.003. Epub 2012 Jan 30.
9
Brucellosis: review on the recent trends in pathogenicity and laboratory diagnosis.布鲁氏菌病:致病性与实验室诊断最新趋势综述
J Lab Physicians. 2010 Jul;2(2):55-60. doi: 10.4103/0974-2727.72149.
10
Update on brucellosis: therapeutic challenges.布鲁氏菌病的最新治疗进展:挑战与对策。
Int J Antimicrob Agents. 2010 Nov;36 Suppl 1:S18-20. doi: 10.1016/j.ijantimicag.2010.06.015. Epub 2010 Aug 6.

人类布鲁氏菌病复发的危险因素。

Risk Factors for Relapse of Human Brucellosis.

作者信息

Hasanjani Roushan Mohammad Reza, Moulana Zahra, Mohseni Afshar Zeinab, Ebrahimpour Soheil

机构信息

Infectious Diseases and Tropical Medicine ResearchCenter, Babol University of Medical Sciences, Babol, Iran.

出版信息

Glob J Health Sci. 2015 Nov 3;8(7):77-82. doi: 10.5539/gjhs.v8n7p77.

DOI:10.5539/gjhs.v8n7p77
PMID:26925907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4965643/
Abstract

BACKGROUND & PROPOSE: Brucellosis is serious disease around the world, especially in underdeveloped countries. Relapse is major problem in therapy of brucellosis. This study aimed to evaluate risk factors of relapse after treatment in patients.

METHODS

It is a descriptive-analytic study from 1990 to 2014, in Ayatolla Rohani hospital in Babol, Iran. We studied 980 patients with brucellosis. The studied community included patients infected with brucellosis and the required information was gathered based on their hospital files. The base for recognizing Malta fever were clinical symptoms and Para-clinical sign congruent with infection like as, titer SAT>1:320 and 2-ME>1:160. Patients with relapse and patients without relapse were placed separately in two groups. The data were statistically compared with Spss 16, by Chi-square and Cox -regression tests.

RESULTS

Based on this study, treatment regimen is a preventive factor (P=0.000). Moreover, Based on some statistical methods, regimens no. 3 and 4 were introduce preventive factors (P=0.001) and (P=0.004). It should also be noted that findings the same statistical model, factors like gender, age, residence, professional contacts, complications and delay in treatment were also analyzed but none of them are considered as preventive factors.

CONCLUSION

Based our finding, we suggest aminoglycosides (gentamicin or streptomycin with doxycycline) are associated with lower rate of relapse in brucellosis.

摘要

背景与目的

布鲁氏菌病是一种全球性的严重疾病,在不发达国家尤为突出。复发是布鲁氏菌病治疗中的主要问题。本研究旨在评估患者治疗后复发的危险因素。

方法

这是一项1990年至2014年在伊朗巴博勒的阿亚图拉·鲁哈尼医院进行的描述性分析研究。我们研究了980例布鲁氏菌病患者。研究群体包括感染布鲁氏菌病的患者,所需信息基于他们的医院档案收集。诊断马耳他热的依据是临床症状和与感染相符的亚临床体征,如血清凝集试验(SAT)滴度>1:320和2-巯基乙醇(2-ME)>1:160。复发患者和未复发患者分别分为两组。数据通过卡方检验和Cox回归检验在Spss 16中进行统计学比较。

结果

基于本研究,治疗方案是一个预防因素(P=0.000)。此外,基于一些统计方法,方案3和方案4被确定为预防因素(P=0.001)和(P=0.004)。还应注意的是,在相同的统计模型中,对性别、年龄、居住地、职业接触、并发症和治疗延迟等因素也进行了分析,但它们均未被视为预防因素。

结论

基于我们的研究结果,我们建议氨基糖苷类药物(庆大霉素或链霉素联合强力霉素)与布鲁氏菌病较低的复发率相关。